A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
暂无分享,去创建一个
Michael J. Emanuele | S. Elledge | Kwok-Kin Wong | C. Creighton | T. Westbrook | Ji Luo | Danan Li | M. Schlabach | Thomas F. Westbrook | Kwok-kin Wong
[1] Robert A. Weinberg,et al. Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.
[2] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] Ji Luo,et al. Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.
[4] S. Haggarty,et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.
[5] Timothy J Mitchison,et al. Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.
[6] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[7] P. Jackson,et al. The Evi5 Oncogene Regulates Cyclin Accumulation by Stabilizing the Anaphase-Promoting Complex Inhibitor Emi1 , 2006, Cell.
[8] M. Kirschner,et al. Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition , 2007, Cell.
[9] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[10] A. Giaccia,et al. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[11] Daigo Inoue,et al. A direct link of the Mos–MAPK pathway to Erp1/Emi2 in meiotic arrest of Xenopus laevis eggs , 2007, Nature.
[12] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[13] Hongmao Sun,et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[14] Igor Jurisica,et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.
[15] Stephen S. Taylor,et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery , 2008, Nature.
[16] A. Catling,et al. Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E , 1998, The Journal of cell biology.
[17] William C Hahn,et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.
[18] AC Tose. Cell , 1993, Cell.
[19] S. Elledge,et al. Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair , 2007, Cell.
[20] J. Ferrell,et al. Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts. , 1998, Science.
[21] J. Peters,et al. Emi1 Is a Mitotic Regulator that Interacts with Cdc20 and Inhibits the Anaphase Promoting Complex , 2001, Cell.
[22] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[23] J. Peters. The anaphase promoting complex/cyclosome: a machine designed to destroy , 2006, Nature Reviews Molecular Cell Biology.
[24] Tomoko Nishiyama,et al. Phosphorylation of Erp1 by p90rsk is required for cytostatic factor arrest in Xenopus laevis eggs , 2007, Nature.
[25] Liming Yang,et al. A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.
[26] K. Kinzler,et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery , 2001, Nature Biotechnology.
[27] B. Ness,et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. , 1996, Blood.
[28] Stephen J. Elledge,et al. Genetic Analysis of the Kinetochore DASH Complex Reveals an Antagonistic Relationship with the Ras/Protein Kinase A Pathway and a Novel Subunit Required for Ask1 Association , 2005, Molecular and Cellular Biology.
[29] M. Urashima,et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. , 1997, Journal of immunology.
[30] S. Fesik,et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells , 2007, Molecular Cancer Therapeutics.
[31] Patrick J. Paddison,et al. Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.
[32] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[33] U. Klein,et al. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. , 2006, Molecular cell.
[34] A. Sweet-Cordero,et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.
[35] S. Shirasawa,et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.
[36] S. Elledge,et al. Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells , 2007, Cell.
[37] D Puthier,et al. High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.
[38] B. Ness,et al. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response , 2002, Oncogene.
[39] R. Kaiser,et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Xiaoling Wang,et al. Cancer cells and normal cells differ in their requirements for Thoc1. , 2007, Cancer research.
[41] Péter Lénárt,et al. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. , 2008, Developmental cell.
[42] P. Jackson,et al. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. , 2004, Molecular biology of the cell.
[43] A. Ullrich,et al. Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.
[44] Stephen J. Elledge,et al. Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.
[45] Péter Lénárt,et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.
[46] J. Minna,et al. The RASSF1A Tumor Suppressor Restrains Anaphase-Promoting Complex/Cyclosome Activity during the G1/S Phase Transition To Promote Cell Cycle Progression in Human Epithelial Cells , 2008, Molecular and Cellular Biology.
[47] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[48] J. Yates,et al. Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry , 2008, Science.
[49] M. Campbell,et al. PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.
[50] Erich A. Nigg,et al. Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.
[51] S. Fesik,et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. , 2007, Cancer research.
[52] R. Deshaies,et al. COP9 Signalosome A Multifunctional Regulator of SCF and Other Cullin-Based Ubiquitin Ligases , 2003, Cell.